VIR News and Press, Vir Biotechnology Inc. From 10/11/23

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association ...

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m....

2023-10-03 09:50:40 ET More on Vir, Xencor, etc. Vir Biotechnology: Strong Balance Sheet But Commercial Prospects Await Further Clarity Vir Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Presentation Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript ...

– New investment of approximately $50 million from Biomedical Advanced Research and Development Authority includes $40 million in Project NextGen funds – – Contract expands existing support for the development of candidates for prevention and treatment of pa...

– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases and cond...

2023-09-08 11:40:55 ET More on Vir Biotechnology Seeking Alpha’s Quant Rating on Vir Biotechnology Historical earnings data for Vir Biotechnology Financial information for Vir Biotechnology Vir Biotechnology: Strong Balance Sheet But Commercial Prospec...

Avalon GloboCare Corp ., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled “QTY Fc...

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical laboratory services is projected to grow from $213 billion in 2022 to a stagger...

SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of September: Morgan Stanley 21 st Annual Global Healthcare Conference at the Sh...

2023-08-21 05:04:54 ET Summary Vir Biotechnology recently released its Q2 2023 earnings and has experienced a drop in stock price due to a setback in its Phase 2 trials. The company has a diverse clinical pipeline focused on infectious diseases and respiratory conditions, with sig...